Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: A randomized, double-blind, active-controlled, parallel group, multinational clinical trial

Diabetes, Obesity and Metabolism

Volumn 17, Issue 2, 2015, Pages 136-144

  Ross, Stuart A ^a   Caballero, A E ^b   Del Prato, S ^c   Gallwitz, B ^d   Lewis D'Agostino, D ^e   Bailes, Z ^f   Thiemann, S ^g   Patel, S ^f   Woerle, H J ^g   von Eynatten, M ^g  

^a UNIVERSITY OF CALGARY   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f BOEHRINGER INGELHEIM LTD   (United Kingdom)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Antidiabetes drug; Clinical trial; DPP 4 inhibitor; Metformin; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ABDOMINAL DISTENSION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEADACHE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE OBSTRUCTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT REDUCTION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INTERNATIONAL COOPERATION; MULTICENTER STUDY; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INTERNATIONAL COOPERATION; METFORMIN; PURINES; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84921419398     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12399     Document Type: Article

References (38)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
3. Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
4. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
5. Del Prato S, Penno G, Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care 2009; 32(Suppl. 2): S217-S222.
6. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36(Suppl. 2): S127-S138.
7. Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36(Suppl. 2): S139-S144.
8. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
9. Garber AJ, Abrahamson MJ, Barzilay JI et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013; 19: 327-336.
10. Harper W, Clement M, Goldenberg R et al. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: pharmacologic management of type 2 diabetes. Can J Diabetes 2013; 37: S61-S68.
11. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin 2011; 27(Suppl. 3): 13-20.
12. Tradjenta (linagliptin) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc., 2013.
13. Trajenta (linagliptin). Summary of product characteristics. Ingelheim, Germany: Boehringer Ingelheim International GmbH & Co. KG. 2013.
14. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet 2012; 51: 411-427.
15. Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-1760.
16. Jentadueto (linagliptin and metformin hydrochloride) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc., 2014.
17. Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin 2012; 28: 969-977.
18. Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther 2012; 29: 1-13.
19. Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011; 27: 1157-1168.
20. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80, 000 people. Diabetes Care 2013; 36: 3411-3417.
21. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 410-417.
22. Nathan DM, Buse JB, Kahn SE et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 2013; 36: 2254-2261.
23. Del Prato S, Foley JE, Kothny W et al. Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. Diabet Med 2014; 31: 1178-1184.
24. Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011; 54: 219-222.
25. Bennett WL, Maruthur NM, Singh S et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613.
26. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
27. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab 2014; 16: 30-37.
28. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987.
29. Reasner C, Olansky L, Seck TL et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 644-652.
30. Wainstein J, Katz L, Engel SS et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 409-418.
31. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 506-515.
32. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-622.
33. Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab 2014; 16: 613-621.
34. Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012; 14: 565-574.
35. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010; 33: 1859-1864.
36. Lim S, An JH, Shin H et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf) 2012; 77: 215-223.
37. Mannucci E, Pala L, Ciani S et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168-1172.
38. King WM 4th, McDermott MT, Trujillo JM. Initial management of severe hyperglycemia in patients with type 2 diabetes: an observational study. Diabetes Ther 2013; 4: 375-384.